

# Tadimeti S Rao

SCIENTIFIC DIRECTOR & FELLOW at Janssen, Pharmaceutical Companies of Johnson and Johnson

---

## Summary

A well-rounded Pharmacologist /Preclinical Development Scientist with a proven track record of advancing ligands targeting GPCRs, Ion Channels, Nuclear Hormone Receptors and Enzymes from concept to clinic in Metabolic Diseases, Inflammation/ Pain, Neuroscience, Autoimmune Diseases, and Oncology. Expertise in Pharmacology/Physiology, ADME/PK; clinical pharmacology, Safety Pharm, IND-enabling GLP studies & Managing CRO's and outsourcing US/China).

Successful track record of drug-hunting reflected in multiple INDs. Team work, collaboration and productivity reflected in more than 90 Peer-reviewed original research publications.

Specialties: Pharmacology & Preclinical Development

Therapeutic Areas: Inflammation, Autoimmune Diseases, Metabolic Diseases, Neuroscience and Oncology, Pharmacokinetics (non-clinical and clinical)

---

## Experience

**SCIENTIFIC DIRECTOR & FELLOW at Janssen, Pharmaceutical Companies of Johnson and Johnson**

2012 - Present

**Research Fellow, Pharmacology at Johnson and Johnson**

2009 - June 2012 (3 years 5 months)

Leading a team of researchers focusing on Pharmacology of Autoimmune and Respiratory Diseases

**Director, Pharmacology & Preclin Dev at Kalypsys Inc**

2003 - September 2009 (6 years 8 months)

Built Pharmacology & Preclinical Development Functions

in support of advancement of leads in Met Dis, Inflammation and Oncology programs to Development. Key member of therapeutic area strategy & portfolio management.

[www.kalypsys.com](http://www.kalypsys.com)

**Senior Research Fellow at Merck**

1998 - 2003 (5 years)

Co-directed Multiple Sclerosis Project and successfully built multi-site collaborations in support of Neuroinflammation Therapeutic Area

Key Member of the Neurodegeneration Team at MRL

**Associate Director**

1993 - 1998 (5 years)

Built Pharmacology /DMPK functions in support of multiple programs; initiated Pain & Neurodegeneration efforts. Two nAChR agonists advanced to clinic: SIB-1508Y[Alitine] for Parkinson's disease (AD) and SIB-1553A for Alzheimer's disease (AD).

**Research Scientist**

1988 - 1993 (5 years)

Built a pharmacology lab to support Inflammation research focused on several eicosanoid and leukotriene targets & CNS research focused on excitatory amino acid receptors. Applications of Mass Spectrometry for early ADME-PK and pharmacology.

**Visiting Scientist at Ciba-Geigy**

1987 - 1988 (1 year)

Post-doctoral Visiting Scientist

Excitatory Amino Acid Receptor Pharmacology

Applications of Mass Spectrometry & microdialysis for studying change in neurotransmitter dynamics

**Formulation Development Scientist**

1982 - 1983 (1 year)

Formulation Research (Parenteral and oral dose formulations) and Post-market stability

---

Education

**University of Alberta**

PhD, Neuroscience, 1983 - 1986

**Andhra University**

M. Pharm, Pharmaceutics, 1980 - 1982

**Andhra University**

B. Pharm., Pharmacy, 1975 - 1979

---

## Tadimeti S Rao

SCIENTIFIC DIRECTOR & FELLOW at Janssen, Pharmaceutical Companies of Johnson and Johnson

---



[Contact Tadimeti S on LinkedIn](#)